CLINICAL TRIAL PROFILE · UPDATED 2026-09-29

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

NCT06953089 · Phase 2 · Recruiting

PHASEPhase 2

STATUSRecruiting

ENROLLMENT450

EST. COMPLETION2030-06-30

Conditions

Solid Tumors

Interventions

DB-1311/BNT324BNT327DB-1305/BNT325

Study details

SPONSORDualityBio Inc.

START DATE2025-07-18

Related company profiles

Duality Biologics

9606.HK

Primary source

ClinicalTrials.gov record NCT06953089 ↗

Trial status and dates can change. Confirm enrollment and eligibility against the linked ClinicalTrials.gov record.

Evidence & limits

Source: Open the source record

Record identifier: NCT06953089
Event / action date: Not separately retained
Source update date: Not separately retained
Platform retrieval / processing date: Not separately retained

What it supports. Study information reported by the sponsor or investigator, including status, phase, enrollment, and recorded dates.

Limits. Registration or completion does not establish clinical success or approval. Sponsor-name associations can be ambiguous. Dates may be estimated; verify the live study record.

Connection basis. Company sponsor aliases and normalized lead-sponsor containment; the NCT identifier identifies the study.

What this record means · Report an issue with this record